...
首页> 外文期刊>BJU international >Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
【24h】

Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.

机译:前列腺增生症患者与非那雄胺相比,联合使用bal和荨麻提取物:分析前列腺体积和治疗效果。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To test the hypothesis that in patients with benign prostatic hyperplasia (BPH), the outcome of drug therapy with finasteride may be predictable from the baseline prostate volume and that positive clinical effects might be expected only in patients with prostate volumes of > 40 mL, using a subgroup analysis of results from a previously reported clinical trial of finasteride and phytotherapy. PATIENTS AND METHODS: A subgroup of 431 patients was analysed from a randomized, multicentre, double-blind clinical trial involving 543 patients with the early stages of BPH. Patients received a fixed combination of extracts of saw palmetto fruit (Serenoa repens) and nettle root (Urtica dioica) (PRO 160/120) or the synthetic 5alpha-reductase inhibitor finasteride. The patients assessed had valid ultrasonographic measurements and baseline prostate volumes of either 40 mL. All 516 patients were included in the safety analysis. The results of the original trial showed equivalent efficacy for both treatments. RESULTS: The mean (SD) maximum urinary flow (the main outcome variable) increased (from baseline values) after 24 weeks by 1.9 (5.6) mL/s with PRO 160/120 and by 2.4 (6.3) mL/s with finasteride. There were no statistically significant group differences (P = 0.52). The subgroups with small prostates ( 40 mL were similar, at 2.3 (6.1) and 2. 2 (5.3) mL/s, respectively. There were improvements in the International Prostate Symptom Score in both treatment groups, with no statistically significant differences. The subgroup analysis showed slightly better results for voiding symptoms in the patients with prostates of > 40 mL, but there were also improvements in the subgroup with smaller prostates. The safety analysis showed that more patients in the finasteride group reported adverse events and also there were more adverse events in this group than in patients treated with PRO 160/120. CONCLUSION: The present analysis showed that the efficacy of both PRO 160/120 and finasteride was equivalent and unrelated to prostate volume. However, PRO 160/120 had better tolerability than finasteride.
机译:目的:为了检验以下假设:在前列腺增生症(BPH)患者中,非那雄胺的药物治疗结果可以从基线前列腺体积中预测出来,并且只有在前列腺体积> 40 mL的患者中才能预期获得积极的临床效果,使用先前报道的非那雄胺和植物疗法临床试验结果的亚组分析。患者与方法:从一项涉及543名BPH早期患者的随机,多中心,双盲临床试验中分析了431名患者的亚组。患者接受了锯棕榈果实(Serenoa repens)和荨麻根(Urtica dioica)(PRO 160/120)的提取物或合成的5α-还原酶抑制剂非那雄胺的固定组合。评估的患者具有有效的超声检查结果,基线前列腺体积为 40 mL。所有516例患者均被纳入安全性分析。原始试验的结果显示两种疗法的等效疗效。结果:24周后,使用PRO 160/120的平均(SD)最大尿流(主要结果变量)增加1.9(5.6)mL / s,使用非那雄胺增加2.4(6.3)mL / s。两组之间无统计学差异(P = 0.52)。前列腺较小的亚组( 40 mL的亚组的平均值相似,分别为2.3(6.1)和2. 2(5.3)mL / s。两个治疗组的国际前列腺症状评分均有改善,无统计学差异。亚组分析显示,> 40 mL前列腺患者的排尿症状略好,但前列腺较小的亚组也有改善。安全性分析显示,与使用PRO 160/120治疗的患者相比,非那雄胺组中更多的患者报告了不良事件,并且该组中的不良事件也更多。结论:目前的分析表明,PRO 160/120和非那雄胺的疗效相同,并且与前列腺体积无关。但是,PRO 160/120的耐受性优于非那雄胺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号